Product Detailed Description

liposomal silybin 70% — High Bioavailability Liver Support Supplement

Product Overview

Liposomal Silybin 70% is a premium-grade dietary supplement ingredient delivering silybin in an advanced liposomal delivery system. Silybin (CAS 22888-70-6), also known as silibinin, is the major flavonolignan of silymarin, a flavonoid complex extracted from the seeds of Silybum marianum (L.) Gaertn., commonly known as milk thistle. It is a mixture of two diastereomers (silybin A and silybin B) present in a 1:1 ratio, accounting for 60–70% of the total silymarin content. The compound is chemically characterized by the molecular formula C₂₅H₂₂O₁₀ and a molecular weight of 482.44 g/mol.

Silybin has attracted widespread attention for its hepatoprotective effects and favorable safety profile, possessing multiple health-promoting activities including antioxidant, anticancer, and hepatoprotective properties. It acts through multiple mechanisms, including binding to hepatocyte membrane proteins, inhibiting lipid peroxidation to stabilize membrane permeability, supporting the liver‘s synthesis of protective substances, and preventing damage from harmful substances.

Why Liposomal Technology?

Conventional silybin presents significant formulation challenges. The compound has extremely poor water solubility, low permeability, and poor bioavailability. Approximately 20% to 50% of its active components are absorbed after oral administration, with about 80% secreted via bile and 10% entering the enterohepatic circulation, resulting in an oral bioavailability of just 0.73%. Silybin is poorly water-soluble, and only 20–50% is absorbed from the gut.

Liposomal encapsulation provides four critical advantages:

1. Dramatically Enhanced Bioavailability — A lecithin-based phytosomal-liposomal formulation of silymarin achieved a 3.5-fold higher oral bioavailability compared to silymarin suspension. A silybin liposome formulation using phosphatidylcholine and cholesterol (molar ratio 9:1) achieved 89% encapsulation efficiency and demonstrated superior hepatoprotective effect compared to silybin solution in animal studies. Research indicates that silybin liposomal powder achieves over 10 times higher bioavailability compared to conventional silymarin tablets.

2. Enhanced Hepatoprotection and ROS Prevention — In vitro studies on Chang liver cells showed 1.5-fold better hepatoprotection efficacy for the liposomal formulation compared to free silymarin, and 10-fold better prevention of ROS production in LPS-induced RAW 264.7 macrophages. In an in vivo paracetamol-induced hepatotoxicity model in Wistar rats, the liposomal formulation was more efficacious than silymarin suspension in protecting the liver and reducing associated inflammatory conditions.

3. Targeted Liver Delivery — The liposomal carrier system enables targeted delivery of silybin to hepatocytes and inflammatory cells, enhancing its therapeutic efficacy at the site of action. Targeted liposomes increased the concentration of silybin and prolonged the drug’s retention time in the liver, with the area under the liver‘s pharmacokinetic curve being twice that of silybin injection.

4. Sustained Release — An optimized silybin liposome formulation achieved a sustained drug release of 80% within 20 hours, providing prolonged hepatoprotective activity.

Product Specifications

Key Features

• High Purity — Standardized to ≥70% silybin by HPLC, ensuring consistent active content.

• Liposomal Enhancement — Phospholipid bilayer encapsulation achieves a 3.5-fold higher oral bioavailability compared to silymarin suspension, with 1.5-fold better hepatoprotection and 10-fold better ROS prevention in vitro.

• Targeted Liver Delivery — Liposomal carrier system enables targeted delivery of silybin to hepatocytes and inflammatory cells, with the area under the liver‘s pharmacokinetic curve being twice that of silybin injection.

• Multiple Hepatoprotective Mechanisms — Silybin binds to hepatocyte membrane proteins, inhibits lipid peroxidation to stabilize membrane permeability, supports the liver’s synthesis of protective substances, and prevents damage from harmful substances.

• Clinically Established Dosage — Based on clinical trials, the recommended dose is 280 to 420 mg of a standardized silymarin preparation (calculated as silybin). Treatment for 1–3 months may be required before therapeutic effects are apparent.

• Superior Encapsulation Efficiency — Optimized silybin liposome formulation achieved 89% encapsulation efficiency with sustained drug release of 80% within 20 hours.

• Water-Dispersible — Suitable for capsules, tablets, powder drink mixes, and functional beverages.

• Batch Traceability — Complete COA, HPLC chromatogram, and identity data provided for each batch.

Application & Formulation Guidance

Recommended Dosage

Based on clinical trials, the recommended dose is 280 to 420 mg of a standardized silymarin preparation (calculated as silybin). Treatment for 1–3 months may be required before the therapeutic effects are apparent. A representative pharmaceutical product (Legalon 140) contains 140 mg of silymarin per capsule, with a recommended dose of one capsule three times daily (420 mg/day). A clinical study in type 2 diabetes used 200 mg of silymarin three times a day before meals, resulting in a significant reduction in blood glucose and glycated hemoglobin (HbA1c) levels compared to placebo. For general liver support and antioxidant defense, 280–420 mg daily is commonly used. Liposomal formulations may allow for more efficient utilization of lower doses due to enhanced bioavailability.

Shipping & Lead Time

• Stock Orders: 3–5 business days after payment confirmation.

• Bulk / Custom Orders: 2–3 weeks, depending on quantity and customization requirements.

• Shipping Methods: International Express (FedEx, DHL, UPS), air freight, and sea freight.

• Coverage: Worldwide shipping, including remote areas.